Merck & Co looks to its traditional strengths in foray into follow-on biologics
This article was originally published in Scrip
With sales growth for biologics expected to outpace that in the overall pharma sector over the next few years, it is not surprising that big pharma has been beefing up its presence in the sector through acquisitions and licensing deals.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.